Table 4.
ARMOR2: galeterone efficacy summary
| Cohort | Number of patients | Any PSA decline | Best response by PCWG2 |
|---|---|---|---|
| Non-metastatic (M0-TN) mCRPC | 21 | 21 (100%) | No evidence of metastasis at 12 weeks |
| Metastatic (M1-TN) mCRPC | 39 | 35 (90%) | Stable disease: 75% |
| Abi-R mCRPC | 30 | 11 (37%) | Stable disease: 47% |
| Enz-R mCRPC | 9 | 4 (44%) | Stable disease: 57% |
Note: Data from Taplin et al.70
Abbreviations: mCRPC, metastatic castration-resistant prostate cancer; TN, treatment-naïve; Abi-R, abiraterone refractory; Enz-R, enzalutamide refractory; PCWG2, Prostate Cancer Working Group 2; PSA, prostate specific antigen.